• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用机器学习发现新型脑脊液生物标志物以预测痴呆进展。

Discovery of novel CSF biomarkers to predict progression in dementia using machine learning.

机构信息

Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.

出版信息

Sci Rep. 2023 Apr 21;13(1):6531. doi: 10.1038/s41598-023-33045-x.

DOI:10.1038/s41598-023-33045-x
PMID:37085545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121677/
Abstract

Providing an accurate prognosis for individual dementia patients remains a challenge since they greatly differ in rates of cognitive decline. In this study, we used machine learning techniques with the aim to identify cerebrospinal fluid (CSF) biomarkers that predict the rate of cognitive decline within dementia patients. First, longitudinal mini-mental state examination scores (MMSE) of 210 dementia patients were used to create fast and slow progression groups. Second, we trained random forest classifiers on CSF proteomic profiles and obtained a well-performing prediction model for the progression group (ROC-AUC = 0.82). As a third step, Shapley values and Gini feature importance measures were used to interpret the model performance and identify top biomarker candidates for predicting the rate of cognitive decline. Finally, we explored the potential for each of the 20 top candidates in internal sensitivity analyses. TNFRSF4 and TGF [Formula: see text]-1 emerged as the top markers, being lower in fast-progressing patients compared to slow-progressing patients. Proteins of which a low concentration was associated with fast progression were enriched for cell signalling and immune response pathways. None of our top markers stood out as strong individual predictors of subsequent cognitive decline. This could be explained by small effect sizes per protein and biological heterogeneity among dementia patients. Taken together, this study presents a novel progression biomarker identification framework and protein leads for personalised prediction of cognitive decline in dementia.

摘要

为个体痴呆患者提供准确的预后仍然是一个挑战,因为他们的认知下降速度有很大差异。在这项研究中,我们使用机器学习技术,旨在识别预测痴呆患者认知下降速度的脑脊液(CSF)生物标志物。首先,我们使用 210 名痴呆患者的纵向简易精神状态检查评分(MMSE)创建快速和缓慢进展组。其次,我们在 CSF 蛋白质组谱上训练随机森林分类器,并为进展组获得了性能良好的预测模型(ROC-AUC=0.82)。作为第三步,使用 Shapley 值和基尼特征重要性度量来解释模型性能并确定预测认知下降速度的顶级生物标志物候选物。最后,我们在内部敏感性分析中探索了每个前 20 个候选物的潜力。TNFRSF4 和 TGF-β1 作为顶级标志物脱颖而出,与进展缓慢的患者相比,快速进展的患者中这些标志物的含量较低。与快速进展相关的低浓度蛋白质富含细胞信号和免疫反应途径。我们的顶级标志物中没有一个是随后认知能力下降的强有力的个体预测因子。这可以用每个蛋白质的小效应大小和痴呆患者之间的生物学异质性来解释。总之,这项研究提出了一种新的进展生物标志物识别框架和用于痴呆患者认知下降个体化预测的蛋白质线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/45ef136d979c/41598_2023_33045_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/fbea62321aa9/41598_2023_33045_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/bd1645998ae7/41598_2023_33045_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/7e3ab88a051d/41598_2023_33045_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/45ef136d979c/41598_2023_33045_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/fbea62321aa9/41598_2023_33045_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/bd1645998ae7/41598_2023_33045_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/7e3ab88a051d/41598_2023_33045_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a80/10121677/45ef136d979c/41598_2023_33045_Fig4_HTML.jpg

相似文献

1
Discovery of novel CSF biomarkers to predict progression in dementia using machine learning.利用机器学习发现新型脑脊液生物标志物以预测痴呆进展。
Sci Rep. 2023 Apr 21;13(1):6531. doi: 10.1038/s41598-023-33045-x.
2
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.生物标志物组合对预测轻度认知障碍向阿尔茨海默病痴呆进展的增量价值。
Alzheimers Res Ther. 2017 Oct 10;9(1):84. doi: 10.1186/s13195-017-0301-7.
3
Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.阿尔茨海默病脑脊液生物标志物可预测路易体痴呆的认知衰退。
Mov Disord. 2016 Aug;31(8):1203-8. doi: 10.1002/mds.26668. Epub 2016 Jun 14.
4
Cerebrospinal Fluid Total Tau Protein Correlates With Longitudinal, Progressing Cognitive Dysfunction in Anti-Neural Autoantibody-Associated Dementia and Alzheimer's Dementia: A Case-Control Study.抗神经自身抗体相关痴呆和阿尔茨海默病性痴呆中脑脊液总 tau 蛋白与纵向、进行性认知功能障碍相关:病例对照研究。
Front Immunol. 2022 Mar 3;13:837376. doi: 10.3389/fimmu.2022.837376. eCollection 2022.
5
Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.在一个早期富集的轻度认知障碍样本中,用于预测转化和认知衰退的认知标志物和生物标志物的不同强度。
J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.
6
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.阿尔茨海默病进展中淀粉样蛋白和 tau 生物标志物的相互预测关系:一个经验模型。
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.
7
Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.记忆门诊中伴有正常β-淀粉样蛋白的轻度认知障碍患者向痴呆的进展。
Alzheimers Res Ther. 2019 Dec 5;11(1):99. doi: 10.1186/s13195-019-0557-1.
8
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.非β-淀粉样蛋白/tau 脑脊液标志物可提示阿尔茨海默病的分期和进展。
Alzheimers Res Ther. 2018 Sep 25;10(1):98. doi: 10.1186/s13195-018-0426-3.
9
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.代谢综合征生物标志物与阿尔茨海默病轻中度认知障碍和痴呆阶段的认知衰退速度有关。
Alzheimers Res Ther. 2023 Mar 16;15(1):54. doi: 10.1186/s13195-023-01203-y.
10
Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.NIA-AA 研究框架的应用:在 AIBL 研究中使用脑脊液生物标志物来定义阿尔茨海默病的生物学定义。
J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25.

引用本文的文献

1
Machine learning for cardio-oncology: predicting global longitudinal strain from conventional echocardiographic measurements in cancer patients.心脏肿瘤学中的机器学习:从癌症患者的传统超声心动图测量预测整体纵向应变
Cardiooncology. 2025 May 22;11(1):49. doi: 10.1186/s40959-025-00348-z.
2
Mapping Knowledge Landscapes and Emerging Trends in AI for Dementia Biomarkers: Bibliometric and Visualization Analysis.痴呆生物标志物人工智能知识图谱与新兴趋势:文献计量与可视化分析
J Med Internet Res. 2024 Aug 8;26:e57830. doi: 10.2196/57830.
3
Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?

本文引用的文献

1
CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels.在阿尔茨海默病谱中进行脑脊液蛋白质组谱分析反映了疾病的多因素性质,并确定了特定的生物标志物组合。
Nat Aging. 2022 Nov;2(11):1040-1053. doi: 10.1038/s43587-022-00300-1. Epub 2022 Nov 10.
2
Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.阿尔茨海默病脑脊液和血浆的多平台蛋白质组学分析揭示了与蛋白质平衡和基质体相关的网络生物标志物。
Alzheimers Res Ther. 2022 Nov 17;14(1):174. doi: 10.1186/s13195-022-01113-5.
3
追踪阿尔茨海默病中的神经炎症生物标志物:个体化治疗方法的策略?
J Neuroinflammation. 2024 Jul 30;21(1):187. doi: 10.1186/s12974-024-03163-y.
4
Plasma pTau181 enhances the prediction of future clinical decline in amyloid-positive mild cognitive impairment.血浆磷酸化tau蛋白181增强了对淀粉样蛋白阳性轻度认知障碍未来临床衰退的预测。
Alzheimers Dement (Amst). 2024 Jul 23;16(3):e12621. doi: 10.1002/dad2.12621. eCollection 2024 Jul-Sep.
5
Precise prediction of cerebrospinal fluid amyloid beta protein for early Alzheimer's disease detection using multimodal data.利用多模态数据精确预测脑脊液淀粉样β蛋白以早期检测阿尔茨海默病
MedComm (2020). 2024 Apr 19;5(5):e532. doi: 10.1002/mco2.532. eCollection 2024 May.
6
Risk prediction of inappropriate implantable cardioverter-defibrillator therapy using machine learning.使用机器学习预测不适当的植入式心脏复律除颤器治疗的风险。
Sci Rep. 2023 Nov 9;13(1):19586. doi: 10.1038/s41598-023-46095-y.
The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest.
2023 年的 STRING 数据库:针对任何感兴趣的测序基因组的蛋白质-蛋白质关联网络和功能富集分析。
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646. doi: 10.1093/nar/gkac1000.
4
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.为何临床试验与结局测量同等重要:阿尔茨海默病临床试验中认知结局测量选择和使用的框架。
Alzheimers Dement. 2023 Feb;19(2):708-720. doi: 10.1002/alz.12773. Epub 2022 Sep 10.
5
Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study.炎症相关蛋白质组与老年痴呆症发展的相关性:来自一项大型前瞻性基于人群队列研究的结果。
Alzheimers Res Ther. 2022 Sep 9;14(1):128. doi: 10.1186/s13195-022-01063-y.
6
Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE).多组学跨学科研究整合以加速痴呆生物标志物开发(MIRIADE)。
Front Neurol. 2022 Jul 12;13:890638. doi: 10.3389/fneur.2022.890638. eCollection 2022.
7
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.阿尔茨海默病早期临床试验终点及其临床意义。
J Prev Alzheimers Dis. 2022;9(3):507-522. doi: 10.14283/jpad.2022.41.
8
Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment.用于轻度认知障碍患者认知衰退预后的血浆生物标志物。
Brain Commun. 2022 Jun 14;4(4):fcac155. doi: 10.1093/braincomms/fcac155. eCollection 2022.
9
CSF proteomic signature predicts progression to Alzheimer's disease dementia.脑脊液蛋白质组学特征可预测向阿尔茨海默病痴呆的进展。
Alzheimers Dement (N Y). 2022 Feb 23;8(1):e12240. doi: 10.1002/trc2.12240. eCollection 2022.
10
Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.基质金属蛋白酶 10 与阿尔茨海默病型痴呆进展的风险相关。
Brain. 2022 Jul 29;145(7):2507-2517. doi: 10.1093/brain/awac024.